• Online Features  This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related article  • Related letter  • Similar articles in this journal  Topic Collections  • Oncology  • Skin Cancer  • Dermatology  • Dermatologic Disorders  • Neoplasms  • Diagnosis  • Psoriasis  • Dermatologic Disorders, Other  • Drug Therapy  • Adverse Effects  • Hematology/ Hematologic Malignancies  • Leukemias/ Lymphomas  • Alert me on articles by topic  Social Bookmarking   What's this?

Sophie M. Worobec, MD

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In reply

We respectfully disagree with Di Lernia's comment that patients with pilar MF, F-MF, or folliculotropic cutaneous T-cell lymphoma (CTCL) "should always be considered to have tumor-stage disease."

We are familiar with the 2002 article by van Doorn et al¹ that describes 51 patients with F-MF who had disease-specific survival rates of 68% at 5 years and 26% at 10 years and posits that the prognosis for F-MF is similar to that for epidermotropic tumor-stage disease.¹ However, Di Lernia did not cite 2 more recent reports that give much better survival rates for F-MF. In a 2005 report,² the European Organization for Research on the Treatment of Cancer classifies F-MF as a distinct subgroup. The 5-year survival rate of 86 patients with F-MF is reported to be 80%, while that of 800 patients with classic MF is 88%.² A 2008 report by Gerami et al³ . . . [Full Text of this Article]

AUTHOR INFORMATION


CiteULike    Connotea    Delicious    Digg    Facebook    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Progression of Undiagnosed Cutaneous T-Cell Lymphoma During Efalizumab Therapy
Claudia Hernandez, Sophie M. Worobec, Sujata S. Gaitonde, Monika L. Kiripolsky, and Kristen Aquino
Arch Dermatol. 2009;145(1):92-94.
EXTRACT | FULL TEXT  

RELATED LETTER

Efalizumab and Progression of Undiagnosed Follicular Mycosis Fungoides
Vito Di Lernia
Arch Dermatol. 2009;145(7):843-844.
EXTRACT | FULL TEXT